Theophylline trial for pseudohypoparathyroidism
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.
This Phase 4 study tests whether the medicine theophylline can help people with pseudohypoparathyroidism type 1A or 1B. It may be considered if you’re trying to improve how your body uses parathyroid hormone and manage related calcium levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a known diagnosis of pseudohypoparathyroidism type 1A or 1B
- You are older than 5 years
- You do not have significant kidney disease
- You do not have a history of kidney stones or high urine calcium (hypercalciuria)
- You have no allergy to theophylline
- You do not have serious ongoing medical problems that could make the medicine unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether the medicine theophylline can help people with pseudohypoparathyroidism. You may be eligible only if you already completed a specific earlier randomized Phase 2 study.
This trial tests a new treatment to help people with hypoparathyroidism (a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels) manage their calcium better. It aims to reduce the need for calcium and vitamin D supplements.
This study follows adults with hypoparathyroidism to better understand what symptoms and lab levels change over time. It may help doctors plan future treatments by learning the natural course of the condition, even if you already take standard medicines.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
Hear when a new PHP Ia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.